MiMedx Group (NASDAQ:MDXG) Downgraded to "Hold" Rating by Wall Street Zen

MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Friday.

Separately, Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Tuesday, July 15th.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG traded down $0.30 during midday trading on Friday, hitting $6.42. The company's stock had a trading volume of 669,822 shares, compared to its average volume of 702,843. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.13 and a current ratio of 4.70. The stock's 50 day simple moving average is $6.48 and its 200 day simple moving average is $7.40. The stock has a market capitalization of $948.25 million, a price-to-earnings ratio of 23.78 and a beta of 1.76. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 11.40% and a return on equity of 22.70%. As a group, research analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current year.

Insider Buying and Selling at MiMedx Group

In other news, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The shares were purchased at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer owned 529,530 shares of the company's stock, valued at approximately $3,357,220.20. The trade was a 60.69% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.70% of the company's stock.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently made changes to their positions in the business. Paradigm Capital Management Inc. NY lifted its stake in shares of MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock worth $45,082,000 after acquiring an additional 22,131 shares during the last quarter. Cannell Capital LLC raised its stake in MiMedx Group by 1.1% in the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock worth $35,012,000 after buying an additional 40,235 shares in the last quarter. First Light Asset Management LLC boosted its position in MiMedx Group by 3.3% during the first quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company's stock valued at $26,243,000 after purchasing an additional 109,213 shares in the last quarter. Renaissance Technologies LLC lifted its position in MiMedx Group by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after acquiring an additional 280,327 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in MiMedx Group by 15.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock valued at $17,338,000 after acquiring an additional 238,075 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.